OrthoPediatrics’ (KIDS) Buy Rating Reaffirmed at BTIG Research

BTIG Research reiterated their buy rating on shares of OrthoPediatrics (NASDAQ:KIDS) in a research note released on Monday morning,Benzinga reports. BTIG Research currently has a $29.00 price objective on the stock.

Several other research firms also recently issued reports on KIDS. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Truist Financial set a $22.00 target price on OrthoPediatrics in a research report on Wednesday, August 5th. Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and a consensus price target of $26.44.

OrthoPediatrics Stock Performance

Shares of KIDS stock opened at $22.34 on Monday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The firm has a market cap of $583.30 million, a P/E ratio of -13.30 and a beta of 0.99. The firm’s 50 day moving average price is $22.05 and its 200-day moving average price is $19.10. OrthoPediatrics has a one year low of $14.42 and a one year high of $26.74.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The company had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. As a group, equities research analysts predict that OrthoPediatrics will post -1.14 EPS for the current year.

Insider Transactions at OrthoPediatrics

In related news, major shareholder Jennifer N. Pritzker sold 302,369 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David R. Pelizzon sold 302,369 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $21.01, for a total value of $6,352,772.69. Following the sale, the director owned 6,201,764 shares in the company, valued at approximately $130,299,061.64. This trade represents a 4.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 2,100,000 shares of company stock valued at $46,747,931. 32.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of OrthoPediatrics during the 2nd quarter worth $24,347,000. AIGH Capital Management LLC purchased a new position in OrthoPediatrics in the second quarter valued at $5,161,000. Nantahala Capital Management LLC purchased a new position in OrthoPediatrics in the second quarter valued at $4,636,002. AWM Investment Company Inc. acquired a new stake in OrthoPediatrics in the second quarter valued at $4,537,000. Finally, Granahan Investment Management LLC raised its stake in OrthoPediatrics by 35.1% in the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp. (NASDAQ: KIDS) develops, manufactures and sells orthopedic products designed specifically for children. The company focuses on addressing the distinct anatomical and clinical needs of pediatric patients, offering implants, instruments and related technologies for orthopedic surgery.

Its product portfolio includes solutions for pediatric trauma and deformity correction, scoliosis and spinal disorders, sports medicine, limb lengthening and reconstruction, and neuromuscular conditions.